Chemotherapy

In this video, Daniel DeAngelo, MD, PhD, discusses the results of a study presented at ASH Annual Meeting that examined the addition of blinatumomab to standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia.

In 2024, the treatment landscape for kidney cancer evolved, with new breakthroughs in combination therapies, new challenges and an emphasis on addressing disparities in care.

Historically, Jae H. Park, MD, has not paid much attention to his patients’ weight loss.

SAN ANTONIO — The novel antibody-drug conjugate SHR-A1811 exhibited promising antitumor activity as neoadjuvant treatment for patients with HER2-positive breast cancer, according to data presented at San Antonio Breast Cancer Symposium.

Laura J. van ’t Veer, PhD, will receive the William L. McGuire Memorial Lecture Award at this year’s San Antonio Breast Cancer Symposium, scheduled for Dec. 10-13.

SAN DIEGO — The addition of blinatumomab to chemotherapy extended DFS for children with newly diagnosed B-cell acute lymphoblastic leukemia, according to results of a randomized phase 3 trial presented at ASH Annual Meeting and Exposition.

The addition of preoperative chemoradiotherapy to standard perioperative chemotherapy did not improve survival for certain patients with resectable gastric cancer, according to results of a randomized phase 3 trial.